Erwin Giovanny Mercado Estrada

Erwin Giovanny Mercado Estrada

Auto-generated profile, based on publicly available information

Erwin Giovanny Mercado Estrada

Instituto Mexicano del Seguro Social

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in SAGA: Revista Científica Multidisciplinar
Verified
Journal Article
Open access
PDF file
Carlos Alberto Corona-AriasCarlos Alberto Corona-Arias
Carlos Alberto Corona-Arias
RGRicardo Daniel Corona González
Ricardo Daniel Corona González
ASAmy Scarlet Martínez Salto
Amy Scarlet Martínez Salto
MYManuel Maximiliano Paredes Ydiaquez
Manuel Maximiliano Paredes Ydiaquez
RTRichard Adrian Vergara Trujillo
Richard Adrian Vergara Trujillo
EEErwin Giovanny Mercado Estrada
Erwin Giovanny Mercado Estrada
Medicine shortages have emerged as a persistent global health challenge, affecting both high-income and low- and middle-income countries. This study analyzed the prevalence, duration, recurrence, systemic drivers, and coping strategies associated with shortages in Mexico, Colombia, and Peru, situating the findings within the international context. Using a cross-sectional design with 1,250 participants, results revealed that shortages were most frequent among antimicrobials, oncology agents, insulin, and anesthetics. These shortages not only lasted longer and recurred more often than in other therapeutic categories but also disproportionately affected low-income and rural populations. Coping strategies included therapeutic substitution and private purchasing, but also riskier responses such as resorting to informal markets and treatment abandonment. Participants identified manufacturing failures, import dependence, and procurement weaknesses as the main systemic drivers, consistent with international evidence. The findings highlight that medicine shortages are not isolated events but structural failures embedded within fragile pharmaceutical systems. Addressing them requires proactive, resilient, and equity-focused policies, including early warning systems, resilient procurement models, diversification of supply chains, and targeted protections for vulnerable populations.

5 November 2025 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
RZRicardo Xavier Cárdenas Zambrano
Ricardo Xavier Cárdenas Zambrano
ESErick Adolfo Meza Soto
Erick Adolfo Meza Soto
JAJosé Enrique González Araujo
José Enrique González Araujo
DADaniel Armando Walteros Acero
Daniel Armando Walteros Acero
EEErwin Giovanny Mercado Estrada
Erwin Giovanny Mercado Estrada
YBYahir Oliver Balderas
Yahir Oliver Balderas
The gut microbiota plays a critical role in metabolic, immune, and gastrointestinal homeostasis. Dysbiosis—characterized by reduced microbial diversity, loss of Bifidobacterium and Akkermansia muciniphila, and an increased Firmicutes/Bacteroidetes ratio—has been consistently linked to insulin resistance, chronic inflammation, and metabolic syndrome. This review analyzes multidisciplinary evidence on microbiota modulation through dietary, probiotic, postbiotic, and transplantation-based interventions, integrating findings from global research and contextualizing them within the health frameworks of Mexico, Colombia, and Ecuador. The results highlight that short-chain fatty acids (SCFAs), primarily butyrate and propionate, mediate the beneficial effects of microbial metabolism by enhancing epithelial barrier integrity, regulating appetite hormones, and reducing systemic inflammation through GPR41, GPR43, and GPR109A signaling. Clinical data demonstrate that lean-donor fecal microbiota transplantation and Akkermansia muciniphila supplementation improve insulin sensitivity and lipid metabolism, while postbiotics offer standardized, colonization-independent bioactivity. Regionally, implementation strategies should follow a tiered model: fiber-centered personalized nutrition, ISAPP-aligned microbial formulations, and ecological reset through standardized consortia or fecal microbiota transplantation in severe dysbiosis. These interventions align with the United Nations Sustainable Development Goals (SDG 3, 9, and 12) by promoting sustainable, equitable, and evidence-based healthcare. Overall, microbiota modulation represents a mechanistically grounded and culturally adaptable tool for the prevention and treatment of chronic diseases, bridging global precision medicine with local dietary and ecological realities.

19 October 2025 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
EBEmerson Javier García Ballesteros
Emerson Javier García Ballesteros
MCMontserrat Ceja Casillas
Montserrat Ceja Casillas
JQJosé Uriel Cornejo Quezada
José Uriel Cornejo Quezada
JEJosé Eduardo Velasco Espinal
José Eduardo Velasco Espinal
Luz Elena Prieto GarcerantLuz Elena Prieto Garcerant
Luz Elena Prieto Garcerant
FRFatima Itzel Soto Rios
Fatima Itzel Soto Rios
The growing prevalence of diabetic kidney disease (DKD) underscores the urgent need for therapies that go beyond glycemic control to achieve meaningful renal protection. This multicenter international study evaluated the impact of GLP-1 receptor agonists—semaglutide (Ozempic) and tirzepatide (Mounjaro)—on kidney outcomes in adults with type 2 diabetes mellitus and chronic kidney disease across Mexico, Colombia, and Ecuador. A total of 1,200 participants were followed for 12 months and compared with matched controls under standard care. Both semaglutide and tirzepatide significantly reduced the incidence of the composite renal endpoint (≥40% decline in eGFR, renal replacement therapy, or cardiovascular death) by 22% and 26%, respectively, versus control. The annual decline in estimated glomerular filtration rate was markedly slower in treated groups (−1.2 to −1.3 mL/min/1.73m²/year) compared with standard care (−3.4 mL/min/1.73m²/year), and urinary albumin-to-creatinine ratio decreased by 35–40%. These benefits were consistent across subgroups, including sex, age, CKD stage, and country, and remained significant after adjustment for confounders. The nephroprotective effects observed likely reflect multifactorial mechanisms—hemodynamic stabilization, anti-inflammatory modulation, endothelial protection, and synergy with SGLT2 inhibitors and RAAS blockade. Results parallel those from major global trials such as FLOW, SURPASS-4, and REWIND, confirming reproducible benefits in Latin American populations. Integrating GLP-1 receptor agonists into diabetic kidney disease management may represent a transformative, evidence-based strategy to delay renal failure and reduce cardiovascular mortality worldwide.

3 November 2025 in IECCMEXICO
Verified
Journal Article
Closed access
DMDulce Rocío Flores Montiel
Dulce Rocío Flores Montiel
ARAdrián Jesús Santoyo Rojas
Adrián Jesús Santoyo Rojas
TSTiffany Ivanna Guerrero Solórzano
Tiffany Ivanna Guerrero Solórzano
SPSilvana Cabrera Puentes
Silvana Cabrera Puentes
EEErwin Giovanny Mercado Estrada
Erwin Giovanny Mercado Estrada
ANAlexa Fernanda Uriostegui Navarro
Alexa Fernanda Uriostegui Navarro
Childhood obesity has emerged as a critical global health challenge with growing prevalence across Latin America, particularly in Mexico, Colombia, and Ecuador. This review synthesizes current international evidence on the biological, behavioral, and policy determinants of obesity and evaluates preventive strategies within clinical, educational, and governmental frameworks. Data reveal that fewer than one in five children meet physical activity guidelines, while sugar-sweetened beverage (SSB) consumption and inadequate sleep remain pervasive contributors to metabolic risk. Family-based behavioral programs with at least 26 contact hours and multicomponent school interventions—including daily physical activity, canteen reform, and sleep literacy—produce the most consistent reductions in BMI z-scores and metabolic markers. Fiscal and regulatory measures, such as SSB taxation and front-of-package labeling, complement these interventions by reshaping food environments and reducing health inequities when properly enforced. The integrated Clinic–School–Home–Policy framework proposed in this study offers a sustainable model that aligns individual behavior with supportive environments and governance mechanisms. Long-term success depends on cross-sector collaboration, continuous evaluation, and social participation to ensure equitable access to healthy food, safe physical activity, and sleep-promoting routines. By transforming policy and practice into a unified prevention ecosystem, Latin American nations can reverse current trends and safeguard the health and well-being of the next generation.